Cart
sales@molnova.com
Cyanosafracin B
CAS No. 96996-50-8
Cyanosafracin B( CBR28-1 | Cyanoquinonamine )
Catalog No. M25019 CAS No. 96996-50-8
Cyanosafracin B is a compound which can be used in the synthesis of ecteinascidin ET-743 (an antitumor chemotherapy drug).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 67 | In Stock |
|
| 2MG | 35 | In Stock |
|
| 5MG | 59 | In Stock |
|
| 10MG | 93 | In Stock |
|
| 25MG | 183 | In Stock |
|
| 50MG | 260 | In Stock |
|
| 100MG | 365 | In Stock |
|
| 200MG | 490 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCyanosafracin B
-
NoteResearch use only, not for human use.
-
Brief DescriptionCyanosafracin B is a compound which can be used in the synthesis of ecteinascidin ET-743 (an antitumor chemotherapy drug).
-
DescriptionCyanosafracin B is a compound which can be used in the synthesis of ecteinascidin ET-743 (an antitumor chemotherapy drug).
-
In Vitro——
-
In Vivo——
-
SynonymsCBR28-1 | Cyanoquinonamine
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number96996-50-8
-
Formula Weight549.62
-
Molecular FormulaC29H35N5O6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (45.49 mM)
-
SMILESC[C@H](N)C(NC[C@H]1C2=C(C(C(C)=C(OC)C2=O)=O)C[C@@]3([H])[C@@]4([H])C5=C(O)C(OC)=C(C)C=C5C[C@@](N4C)([H])[C@H](C#N)N31)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
7-Bromoquinazoline-2...
7-Bromoquinazoline-2,4(1H,3H)-Dione is a marine derived natural products found in Pyura sacciformis.
-
Huperzine B
Huperzine-B is a efficient inhibitor of human brain AChE. Huperzine-B can enhance ognitive and protect neuro, may be potentially new drug candidates for Alzheimer's disease therapy.
-
Pivagabine
Pivagabine is a derivative of hydrophobic 4-aminobutyric acid, with neuromodulatory activity. Pivagabine penetrates the blood-brain barrier in rats. Pivagabine antagonizes the effects of foot shock on both GABAA receptor function and corticotropin-releasing factor (CRF) concentrations in rat brain.
